PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6: A61F 2/06

A1

(11) International Publication Number:

WO 99/23977

(43) International Publication Date:

20 May 1999 (20.05.99)

(21) International Application Number:

PCT/US98/23609

(22) International Filing Date:

5 November 1998 (05.11.98)

(30) Priority Data:

60/064,916

7 November 1997 (07.11.97)

us

(71) Applicant: EXPANDABLE GRAFTS PARTNERSHIP [US/US]; P.O. Box 800699, Dallas, TX 75380-0699 (US).

(72) Inventors: PALMAZ, Julio, C.; 636 Ivy Lane, San Antonio, TX 78209 (US). SPRAGUE, Eugene, A.; 8775 Timber Point, San Antonio, TX 78250 (US).

(74) Agent: TOBOR, Ben, D.; Suite 2300, 1360 Post Oak Boulevard, Houston, TX 77056-3023 (US).

(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published


With international search report.

Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.

(54) Title: INTRAVASCULAR STENT AND METHOD FOR MANUFACTURING AN INTRAVASCULAR STENT

(57) Abstract

The invention relates to an intravascular stent wherein the intravascular stent has its inner surface treated to promote the migration of endothelial cells onto the inner surface of the intravascular stent. Particularly, the inner surface of the intravascular stent includes at least one groove. Methods for manufacturing the intravascular stent are also disclosed.



FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	sı	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
ΑT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Моласо	TD .	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav	TM	Turkmenistan
BF	Burkina Faso	GR	Greece		Republic of Macedonia	TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	ΙE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	บร	United States of Americ
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	ΥU	
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	zw	Yugoslavia
CI	Côte d'Ivoire	KP	Democratic People's	NZ	New Zealand	244	Zimbabwe
CM	Cameroon		Republic of Korea	PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	ΚZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

5

10

20

25

30

INTRAVASCULAR STENT AND METHOD FOR MANUFACTURING AN INTRAVASCULAR STENT

RELATED APPLICATIONS

This application claims the benefit of U.S. Provisional Application No. 60/064,916, filed November 7, 1997.

BACKGROUND OF THE INVENTION

1. FIELD OF THE INVENTION

The invention relates to an intravascular stent and method for manufacturing an intravascular stent, wherein the intravascular stent has its inner surface treated to promote the migration of endothelial cells onto the inner surface of the intravascular stent.

2. <u>DESCRIPTION OF RELATED ART</u>

Various types of intravascular stents have been used in recent years. An intravascular stent generally refers to a device used for the support of living tissue during the healing phase, including the support of internal structures. Intravascular stents, or stents, placed intraluminally, as by use of a catheter device, have been demonstrated to be highly efficacious in initially restoring patency to sites of vascular occlusion. Intravascular stents, or stents, may be of the balloon-expandable type, such as those of U.S. Patent Nos. 4,733,665; 5,102,417; or 5,195,984, which are distributed by Johnson & Johnson Interventional Systems, of Warren, New Jersey, as the PalmazTM and the Palmaz-SchatzTM balloon-expandable stents or balloon expandable stents of other manufacturers, as are known in the art. Other types of intravascular stents are known as self-expanding stents, such as Nitinol coil stents or self-expanding stents made of stainless steel wire formed into a zigzag tubular configuration.

Intravascular stents are used, in general, as a mechanical means to solve the most common problems of percutaneous balloon angioplasty, such as elastic recoil and intimal dissection. One problem intraluminal stent placement shares with other revascularization procedures, including bypass surgery and balloon angioplasty, is restenosis of the artery. An

important factor contributing to this possible reocclusion at the site of stent placement is injury to, and loss of, the natural nonthrombogenic lining of the arterial lumen, the endothelium. Loss of the endothelium, exposing the thrombogenic arterial wall matrix proteins, along with the generally thrombogenic nature of prosthetic materials, initiates platelet deposition and activation of the coagulation cascade. Depending on a multitude of factors, such as activity of the fibrinolytic system, the use of anticoagulants, and the nature of the lesion substrate, the result of this process may range from a small mural to an occlusive thrombus. Secondly, loss of the endothelium at the interventional site may be critical to the development and extent of eventual intimal hyperplasia at the site. Previous studies have demonstrated that the presence of an intact endothelial layer at an injured arterial site can significantly inhibit the extent of smooth muscle cell-related intimal hyperplasia. Rapid re-endothelialization of the arterial wall, as well as endothelialization of the prosthetic surface, or inner surface of the stent, are therefore critical for the prevention of low-flow thrombosis and for continued patency. Unless endothelial cells from another source are somehow introduced and seeded at the site, coverage of an injured area of endothelium is achieved primarily, at least initially, by migration of endothelial cells from adjacent arterial areas of intact endothelium.

5

10

15

20

25

Although an in vitro biological coating to a stent in the form of seeded endothelial cells on metal stents has been previously proposed, there are believed to be serious logistic problems related to live-cell seeding, which may prove to be insurmountable. Thus, it would be advantageous to increase the rate at which endothelial cells from adjacent arterial areas of intact endothelium migrate upon the inner surface of the stent exposed to the flow of blood through the artery. At present, most intravascular stents are manufactured of stainless steel and such stents become embedded in the arterial wall by tissue growth weeks to months after placement. This favorable outcome occurs consistently with any stent design, provided it has a reasonably low metal surface and does not obstruct the fluid, or blood, flow through the artery. Furthermore, because of the fluid dynamics along the inner arterial walls caused by blood pumping through the arteries, along with the blood/endothelium interface itself, it has been desired that the stents have a very smooth surface to facilitate migration of endothelial cells onto the surface of the stent. In fact, it has been reported that smoothness of the stent surface

WO 99/23977 PCT/US98/23609

after expansion is crucial to the biocompatibility of a stent, and thus, any surface topography other than smooth is not desired. Christoph Hehriein, et. al., Influence of Surface Texture and Charge On the Biocompatibility of Endovascular Stents, Coronary Artery Disease, Vol. 6, pages 581-586 (1995). After the stent has been coated with serum proteins, the endothelium grows over the fibrin-coated metal surface on the inner surface of the stent until a continuous endothelial layer covers the stent surface, in days to weeks. Endothelium renders the thrombogenic metal surface protected from thrombus deposition, which is likely to form with slow or turbulent flow. At present, all intravascular stents made of stainless steel, or other alloys or metals, are provided with an extremely smooth surface finish, such as is usually obtained by electropolishing the metallic stent surfaces. Although presently known intravascular stents, specific including the Palmaz™ and Palmaz-Schatz™ balloon-expandable stents have been demonstrated to be successful in the treatment of coronary disease, as an adjunct to balloon angioplasty, intravascular stents could be even more successful and efficacious, if the rate and/or speed of endothelial cell migration onto the inner surface of the stent could be increased. Accordingly, the art has sought an intravascular stent, and method for manufacturing an intravascular stent, which may increase the rate of migration of endothelial cells upon the inner surface of the stent after it has been implanted.

SUMMARY OF THE INVENTION

20

25

5

10

15

In accordance with the invention, the foregoing advantage has been achieved through the present intravascular stent having an outer surface and an inner surface. The present invention includes an improvement in such intravascular stents, and an improvement in the method for manufacturing such intravascular stents, by providing at least one groove disposed in the inner surface of the stent. A further feature of the present invention is that the at least one groove may have a width, a length, and a depth, and the width and depth may not vary along the length of the at least one groove. Further features of the present invention are that: the width of the groove may vary along the length of the at least one groove; the depth of the groove may vary along the length of the at least one groove; and both the width and the depth may vary along the length of the at least one groove.

Another feature of the present invention is that the at least one groove may have a length, a longitudinal axis, and a cross-sectional configuration, and the cross-sectional configuration of the at least one groove. An additional feature of the present invention is that the cross-sectional configuration of the at least one groove may not vary along the length of the at least one groove. Further features of the present invention are that the cross-sectional configuration of the at least one groove may be: substantially symmetrical about the longitudinal axis of the at least one groove; substantially triangular shaped; substantially rectangular shaped; substantially square shaped; substantially U shaped.

A further feature of the present invention is that the longitudinal axis of the at least one groove may be disposed: substantially parallel with the longitudinal axis of the stent; substantially perpendicular to the longitudinal axis of the stent; at an obtuse angle with respect to the longitudinal axis of the longitudinal axis of the stent; or at an acute angle with respect to the longitudinal axis of the stent. An additional feature of the present invention is that the groove may have a depth within a range of approximately one-half to approximately ten microns, and the at least one groove may have a width within a range of approximately two to approximately forty microns.

It is believed that the improvements in intravascular stents and in methods for manufacturing intravascular stents of the present invention, when compared with presently known intravascular stents and methods for manufacturing such stents. has the advantage of increasing the rate of migration of endothelial cells upon the inner surface of the intravascular stent.

BRIEF DESCRIPTION OF THE DRAWING

In the drawing:

5

10

15

20

25

FIG. 1 is a partial cross-sectional, perspective view of a portion of a intravascular stent embedded within an arterial wall of a patient;

FIG. 2 is an exploded view of the outlined portion of FIG. 1 denoted at 2;

5

10

15

20

25

FIG. 3 is a partial cross-sectional, perspective view corresponding to FIG. 1 after the passage of time;

FIG. 4 is an exploded view of the outlined portion of FIG. 3 denoted at 4;

FIG. 5 is a partial cross-sectional view of the stent and artery of FIGS. 1 and 3 after a further passage of time;

FIG. 6 is an exploded view of the outlined portion of FIG. 5 denoted at 5;

FIG. 7 is a partial cross-sectional view of the stent and artery of FIG. 5, taken along lines 7-7 of FIG. 5, and illustrates rapid endothelialization resulting in a thin neointimal layer covering the stent;

FIG. 8 is a plan view of an interior portion of an unexpanded intravascular stent in accordance with the present invention; and

FIGS. 9-16 are various embodiments of an exploded view of a groove taken along line 9-9 of FIG. 8, illustrating various cross-sectional configurations and characteristics of various embodiments of grooves in accordance with the present invention.

While the invention will be described in connection with the preferred embodiment, it will be understood that it is not intended to limit the invention of that embodiment. On the contrary, it is intended to cover all alternatives, modifications, and equivalents, as may be included within the spirit and scope of the invention as defined by the appended claims.

DETAILED DESCRIPTION OF THE INVENTION

With reference to FIGS. 1 and 2. an intravascular stent 200 is illustrated being disposed within an artery 290 in engagement with arterial wall 210. For illustrative purposes only, intravascular stent 200, shown in FIGS. 1-6 is a PalmazTM balloon-expandable stent, as is known in the art, stent 200 having an inner surface 201 and an outer surface 202. FIGS. 1 and 2 illustrate stent 200 shortly after it has been placed within artery 290, and after stent 200 has been embedded into arterial wall 210, as is known in the art. FIGS. 1 and 2 illustrate what may be generally characterized as correct placement of an intravascular stent. Stent 200 preferably includes a plurality of metal members, or struts, 203, which may be manufactured of stainless

steel. or other metal materials, as is known in the art. As illustrated in FIGS. 1 and 2, correct placement of stent 200 results in tissue mounds 211 protruding between the struts 203, after struts 203 have been embedded in the arterial wall 210. Struts 203 also form troughs, or linear depressions, 204 in arterial wall 210. Dependent upon the degree of blockage of artery 290, and the type and amount of instrumentation utilized prior to placement of stent 200, the mounds of tissue 211 may retain endothelial cells (not shown).

5

10

15

20

25

With reference to FIGS. 3 and 4, after the passage of time, a thin layer of thrombus 215 rapidly fills the depressions 204, and covers the inner surfaces 201 of stent 200. As seen in FIG. 4, the edges 216 of thrombus 215 feather toward the tissue mounds 211 protruding between the struts 203. The endothelial cells which were retained on tissue mounds 211 can provide for reendothelialization of arterial wall 210.

With reference to FIGS. 5 and 6, endothelial regeneration of artery wall 210 proceeds in a multicentric fashion, as illustrated by arrows 217, with the endothelial cells migrating to, and over, the struts 203 of stent 200 covered by thrombus 215. Assuming that the stent 200 has been properly implanted, or placed, as illustrated in FIGS. 1 and 2, the satisfactory, rapid endothelialization results in a thin tissue layer 218, as shown in FIG. 7. As is known in the art, to attain proper placement, or embedding, of stent 200, stent 200 must be slightly overexpanded. In the case of stent 200, which is a balloon-expandable stent, the balloon diameter chosen for the final expansion of stent 200 must be 10% to 15% larger than the matched diameter of the artery, or vessel, adjacent the site of implantation. As shown in FIG. 7. the diameter Di of the lumen 219 of artery 290 is satisfactory. If the reendothelialization of artery wall 210 is impaired by underexpansion of the stent or by excessive denudation of the arterial wall prior to, or during, stent placement, slower reendothelialization occurs. This results in increased thrombus deposition, proliferation of muscle cells, and a decreased luminal diameter Di, due to the formation of a thicker neointimal layer.

With reference to FIG. 8, an intravascular stent 300 in accordance with the present invention is illustrated. For illustrative purposes only, the structure of intravascular stent 300 is illustrated as being a PalmazTM balloon-expandable stent, as is known in the art, illustrated

WO 99/23977 PCT/US98/23609

in its initial, unexpanded configuration. It should be understood that the improvement of the present invention is believed to be suitable for use with any intravascular stent having any construction or made of any material as will be hereinafter described. Similarly, the improvement of the present invention in methods for manufacturing intravascular stents, is also believed to be applicable to the manufacturing of any type of intravascular stent as will also be hereinafter described.

5

10

15

20

25

As illustrated in FIG. 8, intravascular stent, or stent, 300 has an inner surface 301, and an outer surface 302, outer surface 302 normally being embedded into arterial wall 210 in an abutting relationship. In accordance with the present invention, the inner surface 301 of stent 300 is provided with at least one groove 400. If desired, as will be hereinafter described in greater detail, a plurality of grooves 400 could be provided on, or in. inner surface 301 of stent 300. The use of the term "groove" throughout this specification and in the claims is intended to be construed as: a channel or depression; a notch or a V-shaped or rounded indentation; or a scratch, or a mark, having been made with something sharp or jagged. The at least one groove 400, or grooves, of the present invention may be provided in, or on, the inner surface 301 of stent 300 to provide the at least one groove 400; a chemical or mechanical etching process; use of a laser or laser etching process; use of a diamond-tipped tool; use of any suitable abrasive material; or use of any tool or process, which can provide the desired groove, or grooves, 400 in, or on, the inner surface 301 of stent 300, as will be hereinafter described in greater detail.

As shown in FIG. 8, the at least one groove, or grooves, 400 may be disposed with its longitudinal axis 410 being disposed substantially parallel with the longitudinal axis 305 of stent 300. Alternatively, the longitudinal axis 410 of the at least one groove 400 may be disposed substantially perpendicular to the longitudinal axis 305 of stent 300, as illustrated by groove 400''''; or the longitudinal axis 410 of the groove may be disposed at an obtuse, or acute, angle with respect to the longitudinal axis 305 of stent 300, as illustrated by groove 400'. The angle that groove 400' makes with respect to longitudinal axis 305 is either an acute or an obtuse angle dependent upon from which direction the angle is measured with respect to the

longitudinal axis 305 of stent 300. For example, if the angle between the longitudinal axis of groove 400' and longitudinal axis 305 is measured as indicated by arrows A, the angle is an acute angle. If the angle is measured, as at arrows B, the angle is an obtuse angle.

5

10

15

20

25

Still with reference to FIG. 8, a plurality of grooves 400 may be provided on the inner surface 301 of stent 300, two grooves 400 being shown for illustrative purposes only. Instead of a plurality of individual grooves, such as grooves 400, a single groove 400" could be provided in a serpentine fashion, so as to cover as much of the inner surface 301 of stent 300 as desired. Similarly, the grooves could be provided in a cross-hatched manner, or pattern, as shown by grooves 400'''. Grooves 400, 400', 400'', 400''', and 400'''' could be provided alone or in combination with each other, as desired, to provide whatever pattern of grooves is desired, including a symmetrical, or an asymmetrical, pattern of grooves. It should be noted that the angular disposition and location of the various grooves 400-400"" will vary and be altered upon the expansion of stent 300 within artery 201 (FIG. 1), stent 300 being illustrated in its unexpanded configuration in FIG. 8. Similarly, if stent 300 were a stent made of wire or lengths of wire, the disposition and angular orientation of the grooves formed on such wire, or wire members, would similarly be altered upon the expansion and implantation of such stent. It should be further noted, as previously discussed, that the groove, or grooves, of the present invention may be provided in, or on, the inner surface of any intravascular stent, so as to increase the rate of migration of endothelial cells on, and over, the inner surface of the intravascular stent.

With reference to FIGS. 9-16, various embodiments of groove 400 will be described in greater detail. In general, as seen in FIG. 9, groove 400 has a width W, a depth D, and a length L (FIG. 8). The width W and depth D may be the same, and not vary, along the length L of the groove 400. Alternatively, the width W of the groove may vary along the length L of the groove 400. Alternatively, the depth D of the groove may vary along the length L of the at least one groove. Alternatively, both the width W and the depth D of the groove 400 may vary along the length of the at least one groove. Similarly, as with the location and angular disposition of groove, or grooves, 400 as described in connection with FIG. 8, the width W,

depth D, and length L of the groove, or grooves, 400 can vary as desired, and different types and patterns of grooves 400 could be disposed on the inner surface 301 of stent 300.

5

10

15

20

25

As shown in FIGS. 9-16, groove 400 may have a variety of different cross-sectional configurations. As desired, the cross-sectional configuration of the groove, or grooves, 400 may vary along the length L of the groove; or the cross-sectional configuration of the groove may not vary along the length of the at least one groove 400. Similarly, combinations of such cross-sectional configurations for the grooves could be utilized. The cross-sectional configuration of the groove, or grooves, 400 may be substantially symmetrical about the longitudinal axis 410 of groove 400 as illustrated in FIGS. 8 and 9; or the cross-sectional configuration of the at least one groove may be substantially asymmetrical about the longitudinal axis 410 of the least one groove, as illustrated in FIGS. 14 and 16. The crosssectional configurations of groove 400 can assume a variety of shapes, some of which are illustrated in FIGS. 9-16, and include those cross-sectional configurations which are substantially: square shaped (FIG. 9); U shaped (FIG. 10); triangular, or V shaped (FIG. 11); rectangular shaped (FIG. 12); and triangular, or keyway shaped (FIG. 13). The wall surface 303 of each groove 400 may be substantially smooth, such as illustrated in FIGS. 9-13, or wall surface 303 may be jagged, or roughened, as illustrated in FIGS. 14 and 16. As illustrated in FIG. 15, wall surface 303 could also be provided with at least one protrusion 304 and at least one indentation 305 if desired, and additional protrusions and indentations 304, 305 could be provided as desired.

The depth D of groove, or grooves, 400 may fall within a range of approximately one-half to approximately ten microns. The width W of groove, or grooves, 400, may fall within a range of approximately two to approximately forty microns. Of course, the width W and depth D could be varied from the foregoing ranges, provided the rate of migration of endothelial cells onto stent 300 is not impaired. The length L of groove 400 may extend the entire length of stent 300, such as groove 400 of FIG. 8; or the length L' of a groove may be less than the entire length of stent 300, such as groove 400'''' in FIG. 8. The groove, or

WO 99/23977 PCT/US98/23609

grooves, of the present invention may be continuous, or discontinuous, along inner surface 301 of stent 300.

The portion of the inner surface 301 of stent 300 which has not been provided with a groove, or grooves, 400 in accordance with the present invention, may have any suitable, or desired, surface finish, such as an electropolished surface, as is known in the art, or may be provided with whatever surface finish or coating is desired. It is believed that when at least one groove in accordance with the present invention is disposed, or provided, on, or in, the inner surface 301 of an intravascular stent 300, after the implantation of stent 300, the rate of migration of endothelial cells upon the inner surface 301 of stent 300 will be increased over that rate of migration which would be obtained if the inner surface 301 were not provided with at least one groove in accordance with the present invention.

5

10

15

It is to be understood that the invention is not limited to the exact details of construction, operation, exact materials, or embodiments shown and described, as obvious modifications and equivalents will be apparent to one skilled in the art. Accordingly, the invention is therefore to be limited only by the scope of the appended claims.

CLAIMS:

1	1.	In an intravascular stent having an outer surface and an inner surface, the
2	impro	ovement comprising:
3		at least one groove disposed in the inner surface of the stent.
1	2.	The improvement of claim 1, wherein the at least one groove has a width, a
2	length	a, and a depth.
1	3.	The improvement of claim 2, wherein the width and depth do not vary along the
2	length	of the at least one groove.
1	4.	The improvement of claim 2, wherein the width of the groove varies along the
2	length	of the at least one groove.
1	5.	The improvement of claim 2, wherein the depth of the groove varies along the
2	length	of the at least one groove.
1	6.	The improvement of claim 2, wherein the width and the depth vary along the
2	length	of the at least one groove.
1	7.	The improvement of claim 1, wherein the at least one groove has a length, a
2	longit	udinal axis, and a cross-sectional configuration.
1	8.	The improvement of claim 7, wherein the cross-sectional configuration of the
2	at leas	t one groove varies along the length of the at least one groove.
1 '.	9.	The improvement of claim 7, wherein the cross-sectional configuration of the
2		t one groove does not vary along the length of the at least one groove.

1	10. The improvement of claim 7, wherein the cross-sectional configuration of the
2	at least one groove is substantially symmetrical about the longitudinal axis of the at
3	least one groove.
1	11. The improvement of claim 7, wherein the cross-sectional configuration of the
2	at least one groove is substantially asymmetrical about the longitudinal axis of the at
3	least one groove.
1	12. The improvement of claim 7, wherein the cross-sectional configuration is
2	substantially triangular shaped.
1	13. The improvement of claim 7, wherein the cross-sectional configuration is
2	substantially rectangular shaped.
1	14. The improvement of claim 7, wherein the cross-sectional configuration is
2	substantially square shaped.
1	15. The improvement of claim 7, wherein the cross-sectional configuration is
2	substantially U shaped.
1	16. The improvement of claim 7, wherein the cross-sectional configuration is
2	substantially V shaped.
1	17. The improvement of claim 1, wherein the stent and the at least one groove each
2	have a longitudinal axis, and the longitudinal axis of the at least one groove is
3	substantially parallel with the longitudinal axis of the stent.
1	18. The improvement of claim 1, wherein the stent and the at least one groove each
2	have a longitudinal axis, and the longitudinal axis of the at least one groove is
3	substantially perpendicular to the longitudinal axis of the stent

WO 99/23977 PCT/US98/23609

19. The improvement of claim 1, wherein the stent and the at least one groove each have a longitudinal axis, and the longitudinal axis of the at least one groove is disposed at an obtuse angle with respect to the longitudinal axis of the stent.

- 20. The improvement of claim 1, wherein the stent and the at least one groove each have a longitudinal axis, and the longitudinal axis of the at least one groove is disposed at an acute angle with respect to the longitudinal axis of the stent.
- 21. The improvement of claim 1, wherein the at least one groove has a depth within a range of approximately one-half to approximately ten microns.
- 22. The improvement of claim 1, wherein the at least one groove has a width within a range of approximately two to approximately forty microns.
- 23. The improvement of claim 1, wherein at least two grooves are disposed in the inner surface of the stent and the at least two grooves are disposed in a cross-hatched pattern on the inner surface of the stent.
- 24. In a method for manufacturing an intravascular stent, the stent having an outer surface and an inner surface, the improvement comprising:

 providing at least one groove in the inner surface of the stent.
- 25. The improvement of claim 24, wherein the at least one groove has a width, a length, and a depth.
- 26. The improvement of claim 25, including the step of not varying the width and depth along the length of the at least one groove.

1	27. The improvement of claim 25, including the step of varying the width of the
2	groove along the length of the at least one groove.
1	28. The improvement of claim 25, including the step of varying the depth of the
2	groove along the length of the at least one groove.
1	29. The improvement of claim 25, including the step of varying the width and the
2	depth along the length of the at least one groove.
1	30. The improvement of claim 24, wherein the at least one groove has a length, a
2	longitudinal axis, and a cross-sectional configuration.
1	31. The improvement of claim 30, including the step of varying the cross-sectional
2	configuration of the at least one groove along the length of the at least one groove.
1	32. The improvement of claim 30, including the step of varying the cross-sectional
2	configuration of the at least one groove along the length of the at least one groove.
1	33. The improvement of claim 30, including the step of providing the cross-
2	sectional configuration of the at least one groove substantially symmetrical about the
3	longitudinal axis of the at least one groove.
1	34. The improvement of claim 30, including the step of providing the cross-
2	sectional configuration of the at least one groove substantially asymmetrical about the
3	longitudinal axis of the at least one groove.
1	35. The improvement of claim 30, including the step of providing the cross-
2	sectional configuration as substantially triangular shaped

36. The improvement of claim 30, including the step of providing the cross-sectional configuration as substantially rectangular shaped.

- 37. The improvement of claim 30, including the step of providing the cross-sectional configuration as substantially square shaped.
- 38. The improvement of claim 30, including the step of providing the cross-sectional configuration as substantially U shaped.
- 39. The improvement of claim 30, including the step of providing the cross-sectional configuration as substantially V shaped.
- 40. The improvement of claim 24, wherein the stent and the at least one groove each have a longitudinal axis, and including the step of providing the longitudinal axis of the at least one groove substantially parallel with the longitudinal axis of the stent.
- 41. The improvement of claim 24, wherein the stent and the at least one groove each have a longitudinal axis, and including the step of providing the longitudinal axis of the at least one groove substantially perpendicular to the longitudinal axis of the stent.
- 42. The improvement of claim 24, wherein the stent and the at least one groove each have a longitudinal axis, and including the step of providing the longitudinal axis of the at least one groove disposed at an obtuse angle with respect to the longitudinal axis of the stent.
- 43. The improvement of claim 24, wherein the stent and the at least one groove each have a longitudinal axis, and including the step of providing the longitudinal axis of the at least one groove disposed at an acute angle with respect to the longitudinal axis of the stent.

WO 99/23977

1

2

1

2

3


1

2


micron	S.	,	
groove	with a depth within a range of approximately one-half to approxim	ately	ten
44.	The improvement of claim 24, including the step of providing the at	least	one


- 45. The improvement of claim 24, including the step of providing the at least one groove with a width within a range of approximately two to approximately forty microns.
- 46. The improvement of claim 24, including the step of providing at least two grooves in the inner surface of the stent and providing the at least two grooves in a cross-hatched pattern.







SUBSTITUTE SHEET (RULE 26)







SUBSTITUTE SHEET (RULE 26)



Intern ial Application No.

			101/03 90,	
A. CLASSI IPC 6	FICATION OF SUBJECT MATTER A61F2/06			
According to	o International Patent Classification (IPC) or to both national classification	and IPC		•
	SEARCHED			
	ocumentation searched (classification system followed by classification sy A61F	mbols)		
- · · ·				
Documental	tion searched other than minimum documentation to the extent that such o	documents are inclu	ded in the fields se	arched
Clearence				
riectronic d	ata base consulted during the international search (name of data base an	id. where practical.	search terms used	
		4		
	ENTS CONSIDERED TO BE RELEVANT			
Category :	Citation of document, with indication, where appropriate, of the relevant	passages		Relevant to claim No.
Y	US 4 869 714 A (DEININGER WILLIAM D AL) 26 September 1989	ET .	:	1,7,9, 10,18, 21,24, 30,32, 33,41,44
•	see figures 1,2 see column 2, line 28 - line 60			
	-/-	<u>-</u>		
		٠		·
-				
			,	
		·····		
ستا	ner documents are listed in the continuation of box C.	Patent family n	nembers are listed	in annex.
* Special ca	tegories of cited documents : "T" I	aler document publ	ished after the inte	mational filing date
consid	ent defining the general state of the art which is not ered to be of particular relevance	or priority date and	not in conflict with	the application but eory underlying the
filing d	410	document of particu cannot be consider	lar relevance; the c red novel or cannot	laimed invention be considered to
which	Int which may throw doubts on priority claim(s) or is cited to establish the publication date of another "y" or other special reason (as specified)	involve an inventive document of particu	e step when the do- lar relevance; the c	cument is taken alone laimed invention
	ant referring to an oral disclosure, use, exhibition or	document is combi ments, such combi	ned with one or mo	ventive step when the fre other such docu- us to a person skilled
"P" docume later th	ent published prior to the international filling date but an the priority date claimed "&"	in the art. document member of	-	·
Date of the	actual completion of the international search	Date of mailing of t	he international sea	arch report
2	March 1999	23/03/19	999	
Name and r	nailing address of the ISA European Patent Office, P.B. 581.8 Patentlaan 2	Authorized officer		
	NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016	Mary, C		

Intern (all Application No PCT/US 98/23609

C (C) :::		PCT/US 9	8/23609
	ation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category	Citation of document, with indication, where appropriate, of the relevant passages		Relevant to claim No.
Υ,Ρ	EP 0 850 604 A (SORIN BIOMEDICA SPA) 1 July 1998		1,7,9, 10,18, 21,24, 30,32,
A	see column 3, line 8 - line 18		33,41,44 2-6,8, 11-17, 19,20, 22,23, 25-29, 31, 34-40, 42,43,
			45,46
	see column 3, line 54 - column 4, line 12 see column 4, line 21 - line 34 see column 5, line 25 - line 55 see claims 1,2,15,16,18,28 see figures 1-6		
Y	RATNER: "New ideas in biomaterials science" J BIOMED MATER RES, vol. 27, 1993, pages 837-850, XP002095201 see page 843, column 2, line 1 - line 17		1,24
Y	PALMAZ: "New advances in endovascular Technology"		1,24
	TEX HEART INST J, vol. 24, no. 3, 1997, pages 156-159, XP002095202 see page 156, line 20 - line 29 see page 157, column 2, line 36 - line 53		
A.P	WO 97 42910 A (CARDIA CATHETER CO) 20 November 1997 see figures 7-10 see figures 17-19 see page 10, line 35 - page 11, line 36 see page 21, line 22 - page 22, line 6 see page 26, line 5 - line 14 see claim 1	·	1-46
	-/		
	,		

Form PCT/ISA/210 (continuation of second sheet) (July 1992)

Interr hal Application No PCT/US 98/23609

		PC1/US 98/23609		
	ation) DOCUMENTS CONSIDERED TO BE RELEVANT	Relevant to claim No. ICDONALD EDWARD A ET AL) 1-3,7,9, 10,13, 18,21, 22, 24-26, 30,32, 33,36, 41,44,45 ne 61 - column 8, line 64 ne 66 - column 11, line ne 54 - column 12, line		
Category	Citation of document, with indication, where appropriate, of the relevant passages	•		
A,P	US 5 728 150 A (MCDONALD EDWARD A ET AL) 17 March 1998	1-3,7,9, 10,13, 18,21, 22, 24-26, 30,32, 33,36,		
	see column 7, line 61 - column 8, line 64 see column 10, line 66 - column 11, line 32	41,44,45		
	see column 11, line 54 - column 12, line 11 see figures 2,6			
A	EP 0 701 803 A (AO FORSCHUNGSINST) 20 March 1996 see abstract see claims 1,8 see figure 3	1,24		
				
		•		

information on patent family members

Interi nal Application No PCT/US 98/23609

Patent document cited in search report		Publication date			Publication date
US 4869714	Α	26-09-1989	US	4767418 A	30-08-1988
EP 0850604	Α	01-07-1998	IT	T0961095 A	30-06-1998
WO 9742910	А	20-11-1997	AU	3054497 A	05-12-1997
US 5728150	A	17-03-1998	US AU WO · AU WO	5676697 A 5452098 A 9822045 A 4046997 A 9804212 A	14-10-1997 10-06-1998 28-05-1998 20-02-1998 05-02-1998
EP 0701803	Α	20-03-1996	NONE		